Clinical use of temporary percutaneous left ventricular assist devices

Catheter Cardiovasc Interv. 2011 Aug 1;78(2):304-13. doi: 10.1002/ccd.22948. Epub 2011 Jul 15.

Abstract

Background: Temporary percutaneous left ventricular assist devices (TPLVAD) can be inserted and removed in awake patients. They substitute left ventricular function for a period of up to a few weeks and provide an excellent backup and bridge to recovery or decision.

Methods: Retrospective analysis of 75 patients who received TPLVAD to treat cardiogenic shock (n = 49) or to facilitate high-risk percutaneous coronary intervention (PCI) (n = 26). Forty-two patients with cardiogenic shock and 16 patients with high-risk PCI received a TandemHeart and 7 patients and 10 patients, respectively, received an Impella Recover LP 2.5. Outcome and related complications up to 1 month are reported with reference to device depending function.

Results: One-month survival was 53% in patients with shock and 96% in patients with PCI.

Conclusion: TPLVADs can support the failing heart with acceptable risk. Outcome is better in prophylactic use than in patients with cardiogenic shock.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Angioplasty, Balloon, Coronary / mortality
  • Female
  • Heart-Assist Devices* / adverse effects
  • Hospital Mortality
  • Humans
  • Male
  • Middle Aged
  • Patient Selection
  • Prosthesis Design
  • Registries
  • Retrospective Studies
  • Risk Assessment
  • Risk Factors
  • Shock, Cardiogenic / mortality
  • Shock, Cardiogenic / physiopathology
  • Shock, Cardiogenic / therapy*
  • Switzerland
  • Time Factors
  • Treatment Outcome
  • Ventricular Function, Left*
  • Young Adult